Blue Jay Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Blue Jay Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$5.95M	Sell	46,202 -33,959	-42%	-$4.09M	4.06%	17
2017 Q1	$8.77M	Buy	+80,161	New	+$7.06M	4.31%	17
2016 Q3	–	Sell	-125,450	Closed	-$10.8M	–	20
2016 Q2	$10.8M	Buy	+125,450	New	+$10.8M	7.09%	8
2016 Q1	–	Sell	-80,020	Closed	-$10.1M	–	24
2015 Q4	$10.1M	Sell	80,020 -58,118	-42%	-$7.02M	3.39%	18
2015 Q3	$14.4M	Buy	138,138 +23,138	+20%	+$2.97M	5.65%	6
2015 Q2	$14.2M	Buy	115,000 +10,000	+10%	+$1.26M	3.82%	12
2015 Q1	$12.4M	Buy	105,000 +37,500	+56%	+$4.49M	4.35%	14
2014 Q4	$8.02M	Buy	+67,500	New	+$7.6M	3.58%	19

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Blue Jay Capital Management's VRTX Position: Q2 2017 in Review

Blue Jay Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 42% in Q2 2017, selling an estimated $4.09M and leaving 46,202 shares worth $5.95M. The position accounts for 4.06% of the portfolio, ranked #17.

Blue Jay Capital Management first reported a position in VRTX in Q4 2014 and has held it in 8 quarters since. The position peaked at $14.4M in Q3 2015. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

Blue Jay Capital Management held 46,202 shares of Vertex Pharmaceuticals worth $5.95M as of Q2 2017.
Blue Jay Capital Management sold 33,959 Vertex Pharmaceuticals shares in Q2 2017, an estimated $4.09M.
Vertex Pharmaceuticals made up 4.06% of Blue Jay Capital Management's portfolio in Q2 2017, its #17 holding.
Blue Jay Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 8 quarters since.
Blue Jay Capital Management's Vertex Pharmaceuticals position peaked at $14.4M in Q3 2015.
582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on Blue Jay Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.